Novartis presents 10 cardiovascular data points at ESC Congress 2026
Novartis is presenting 10 abstracts at the 2026 ESC Congress, covering Leqvio, Entresto, abelacimab, and pacibekitug. The data aims to reinforce its leadership in cardiovascular care by addressing persistent risks through established and investigational therapies.
*this image is generated using AI for illustrative purposes only.
Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. The presentations cover foundational medicines such as Leqvio and Entresto, alongside promising investigational therapies including abelacimab and pacibekitug.
Ruchira Glaser, M.D., Global Head of Cardiovascular, Renal and Metabolic Development at Novartis , stated that the data underscores the company's commitment to advancing cardiovascular science for patients who remain at risk despite current treatment. The portfolio reflects a focus on addressing persistent challenges in cardiovascular care through bold science and a diverse pipeline.
Key Abstracts Accepted by ESC
The accepted abstracts span multiple therapeutic areas within cardiovascular disease, featuring both approved medicines and investigational candidates.
| Medicine/Disease | Abstract Title | Presentation Details |
|---|---|---|
| Leqvio | Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial | Tripoli (Hall B1); Late-Breaking Oral Presentation; August 31, 08:15-08:30 CEST |
| Leqvio | An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial | Exchange Circle 3 (Research Gateway – Hall A1); ePoster; August 29, 09:15-10:00 CEST |
| Abelacimab | Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 | Science Box 2 (Research Gateway – Hall A1); Oral Presentation; August 29, 09:30-10:30 CEST |
| Lipoprotein (a) [Lp(a)] | Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis | Exchange Circle 6 (Research Gateway – Hall A1); ePoster; August 29, 16:15-17:00 CEST |
| Entresto | Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial | Station 5 (Research Gateway – Hall A1); ePoster; August 31, 09:15-10:00 CEST |
| Pacibekitug | TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk | Munich (Main Auditorium-Hall B3); Hot Line; August 29, 08:45-09:00 CEST |
Portfolio Highlights
Key highlights from the presentations include:
- Leqvio: Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate inclisiran against bempedoic acid in achieving LDL-C goals.
- Abelacimab: New AZALEA-TIMI 71 analyses will further characterize the bleeding profile in patients with atrial fibrillation, including recurrent bleeding events.
- Lp(a)CCELERATE: In partnership with the European Atherosclerosis Society (EAS), this initiative will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice.
Historical Stock Returns for Novartis
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.06% | -3.89% | -8.17% | +53.87% | +53.87% | +90.03% |
How might the head-to-head superiority of Leqvio over bempedoic acid in the VICTORION-CHALLENGE trial influence future clinical guidelines for LDL-C management in high-risk patients?
What is the projected timeline for regulatory approval of abelacimab and pacibekitug based on the upcoming ESC data, and how could this reshape Novartis's cardiovascular revenue mix?
Could the implementation strategies highlighted in the Lp(a)CCELERATE initiative significantly increase market penetration for Novartis's Lipoprotein(a)-targeting therapies in Europe?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
